Artwork

Content provided by Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Interview with Dr. Salma Jabbour: An In-depth Look at the PROSPECT Trial

21:16
 
Share
 

Manage episode 373899405 series 2982543
Content provided by Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Salma Jabbour, Clinical Chief, Radiation Oncology and Vice Chair of Clinical Research & Faculty Development at RWJUH/Rutgers Cancer Institute. Together they discuss a plenary presentation that was given at ASCO 2023 on rectal cancer titled, the PROSPECT (Preoperative Radiation or Selective Preoperative Radiation and Evaluation before Chemotherapy and TME) trial. The PROSPECT trial attempts to challenge the current treatment paradigm by individualizing treatment through the use of radiotherapy selectively rather than reflexively. This is a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for the treatment of locally advanced rectal cancer (LARC). For more information, please visit: www.CarisLifeSciences.com
  continue reading

60 episodes

Artwork
iconShare
 
Manage episode 373899405 series 2982543
Content provided by Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Salma Jabbour, Clinical Chief, Radiation Oncology and Vice Chair of Clinical Research & Faculty Development at RWJUH/Rutgers Cancer Institute. Together they discuss a plenary presentation that was given at ASCO 2023 on rectal cancer titled, the PROSPECT (Preoperative Radiation or Selective Preoperative Radiation and Evaluation before Chemotherapy and TME) trial. The PROSPECT trial attempts to challenge the current treatment paradigm by individualizing treatment through the use of radiotherapy selectively rather than reflexively. This is a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for the treatment of locally advanced rectal cancer (LARC). For more information, please visit: www.CarisLifeSciences.com
  continue reading

60 episodes

すべてのエピソード

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide